These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 35321560)

  • 41. Immune checkpoint inhibitor-induced myocarditis with myasthenia gravis overlap syndrome: A case report and literature review.
    Gao L; Li X; Guo Z; Tang L; Peng J; Liu B
    Medicine (Baltimore); 2022 Dec; 101(49):e32240. PubMed ID: 36626474
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neurological adverse events related to immune-checkpoint inhibitors in Spain: a retrospective cohort study.
    Fonseca E; Cabrera-Maqueda JM; Ruiz-García R; Naranjo L; Diaz-Pedroche C; Velasco R; Macias-Gómez A; Milisenda JC; Muñoz-Farjas E; Pascual-Goñi E; Gállego Perez-Larraya J; Saiz A; Dalmau J; Blanco Y; Graus F; Martinez-Hernandez E;
    Lancet Neurol; 2023 Dec; 22(12):1150-1159. PubMed ID: 37977714
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Case Report: Glucocorticoid Effect Observation in a Ureteral Urothelial Cancer Patient With ICI-Associated Myocarditis and Multiple Organ Injuries.
    Hu X; Wei Y; Shuai X
    Front Immunol; 2021; 12():799077. PubMed ID: 34975911
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunotherapy-Induced Overlap Syndrome: Myositis, Myasthenia Gravis, and Myocarditis-A Case Series.
    Aggarwal N; Bianchini D; Parkar R; Turner J
    Case Rep Med; 2024; 2024():5399073. PubMed ID: 38585685
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immune Myocarditis Overlapping With Myasthenia Gravis Due to Anti-PD-1 Treatment for a Chordoma Patient: A Case Report and Literature Review.
    Liang S; Yang J; Lin Y; Li T; Zhao W; Zhao J; Dong C
    Front Immunol; 2021; 12():682262. PubMed ID: 34305915
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Asymptomatic Immune Checkpoint Inhibitor-associated Myocarditis.
    Tanabe J; Watanabe N; Endo A; Nagami T; Inagaki S; Tanabe K
    Intern Med; 2021 Feb; 60(4):569-573. PubMed ID: 33028770
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Life-threatening immune checkpoint inhibitor-induced myocarditis and myasthenia gravis overlap syndrome treated with abatacept: a case report.
    Wakefield C; Shultz C; Patel B; Malla M
    BMJ Case Rep; 2021 Nov; 14(11):. PubMed ID: 34728505
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Immune Checkpoint Inhibitors-induced Myasthenia Gravis: From Diagnosis to Treatment].
    Yao S; Li X; Nong J; Zhang Y
    Zhongguo Fei Ai Za Zhi; 2020 Aug; 23(8):685-688. PubMed ID: 32752585
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [A case of myasthenia gravis and myositis induced by pembrolizumab].
    Noda T; Kageyama H; Miura M; Tamura T; Ito H
    Rinsho Shinkeigaku; 2019 Aug; 59(8):502-508. PubMed ID: 31341124
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Myositis as a neuromuscular complication of immune checkpoint inhibitors.
    Vermeulen L; Depuydt CE; Weckx P; Bechter O; Van Damme P; Thal DR; Claeys KG
    Acta Neurol Belg; 2020 Apr; 120(2):355-364. PubMed ID: 31993961
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Rare Case of Overlapping Durvalumab-induced Myositis, Takotsubo-like Morphological Changes Caused by Myocarditis, and Myasthenia Gravis.
    Saito S; Hontsu S; Hiraoka J; Yamanaka A; Fujioka N; Shimada D; Okuda Y; Sugie K; Muro S
    Intern Med; 2024 Apr; ():. PubMed ID: 38658343
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case series.
    Vicino A; Hottinger AF; Latifyan S; Boughdad S; Becce F; Prior JO; Kuntzer T; Brouland JP; Dunet V; Obeid M; Théaudin M
    J Neurol; 2024 Apr; 271(4):1947-1958. PubMed ID: 38141128
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Distinctive Disease Entity of Neurological Adverse Events Associated with Immune Checkpoint Inhibitors].
    Seki M; Suzuki S
    Brain Nerve; 2021 Jan; 73(1):35-46. PubMed ID: 33361512
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Checkpoint inhibitor-related myasthenia-myocarditis-myositis overlap syndrome in the orbit.
    Park BJ; Warning AW; Akella SS
    Orbit; 2024 May; ():1-7. PubMed ID: 38796779
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis.
    Cautela J; Zeriouh S; Gaubert M; Bonello L; Laine M; Peyrol M; Paganelli F; Lalevee N; Barlesi F; Thuny F
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33298621
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Managing suspected myasthenia gravis and myositis induced by pembrolizumab in a Jehovah's Witness sarcoma patient.
    Hutchinson A; Eskens D; Chan A; Bhargava A; Bycroft R
    J Oncol Pharm Pract; 2024 Jul; 30(5):950-953. PubMed ID: 38523425
    [TBL] [Abstract][Full Text] [Related]  

  • 57. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors.
    Kostine M; Finckh A; Bingham CO; Visser K; Leipe J; Schulze-Koops H; Choy EH; Benesova K; Radstake TRDJ; Cope AP; Lambotte O; Gottenberg JE; Allenbach Y; Visser M; Rusthoven C; Thomasen L; Jamal S; Marabelle A; Larkin J; Haanen JBAG; Calabrese LH; Mariette X; Schaeverbeke T
    Ann Rheum Dis; 2021 Jan; 80(1):36-48. PubMed ID: 32327425
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mogamulizumab-Associated Myositis With and Without Myasthenia Gravis and/or Myocarditis in Patients With T-Cell Lymphoma.
    Virgen CA; Sparks JA; Nohria A; O'Hare MJ; Goyal A; Said JT; Tawa M; LeBoeuf NR; Kupper TS; Fisher DC; Larocca C
    Oncologist; 2023 Aug; 28(8):e694-e698. PubMed ID: 37285523
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Myositis-myasthenia gravis overlap syndrome complicated with myasthenia crisis and myocarditis associated with anti-programmed cell death-1 (sintilimab) therapy for lung adenocarcinoma.
    Xing Q; Zhang ZW; Lin QH; Shen LH; Wang PM; Zhang S; Fan M; Zhu B
    Ann Transl Med; 2020 Mar; 8(5):250. PubMed ID: 32309397
    [TBL] [Abstract][Full Text] [Related]  

  • 60. How we identify and treat neuromuscular toxicity induced by immune checkpoint inhibitors.
    Jordan B; Benesova K; Hassel JC; Wick W; Jordan K
    ESMO Open; 2021 Dec; 6(6):100317. PubMed ID: 34839103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.